Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Revenue of Xencor, Inc. (XNCR)
Revenue in 2023 (TTM): $168.34 M
According to Xencor, Inc.'s latest financial reports the company's current revenue (TTM) is $168.34 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Xencor, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $168.34 M | $-85,260,000 | $-125,874,000 | $-120,439,000 | $-126,087,000 |
| 2022 | $164.58 M | $155.78 M | $-72,164,000 | $-54,508,000 | $-55,181,000 |
| 2021 | $275.11 M | $267.62 M | $51.26 M | $82.63 M | $82.63 M |
| 2020 | $122.69 M | $-47,108,000 | $-71,003,000 | $-69,333,000 | $-63,539,000 |
| 2019 | $156.7 M | $38.11 M | $18.12 M | $27.19 M | $26.88 M |
| 2018 | $40.6 M | $-56,898,000 | $-75,880,000 | $-70,409,000 | $-70,409,000 |
| 2017 | $35.71 M | $-36,061,000 | $-40,697,000 | $-49,388,000 | $-48,925,000 |
| 2016 | $87.52 M | $35.65 M | $45.86 M | $24.62 M | $23.63 M |
| 2015 | $27.76 M | $-6,378,000 | $-16,466,000 | $-17,592,000 | $-17,592,000 |
| 2014 | $9.52 M | $-8,996,000 | $-15,531,000 | $-16,422,000 | $-16,422,000 |
| 2013 | $10.17 M | $-6,828,000 | $-58,335,000 | $-60,258,000 | $-60,258,000 |
| 2012 | $9.52 M | $-3,144,000 | $-5,606,000 | $-8,594,000 | $-8,594,000 |
| 2011 | $6.85 M | $6.85 M | $-8,746,000 | $-11,203,000 | $-11,203,000 |